InflaRx NV (IFRX)
2.23
-0.06
(-2.62%)
USD |
NASDAQ |
Sep 03, 12:49
InflaRx Research and Development Expense (TTM) : 25.38M for June 30, 2026
Research and Development Expense (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 25.38M |
| March 31, 2026 | 27.25M |
| September 30, 2025 | 35.08M |
| June 30, 2025 | 38.57M |
| March 31, 2025 | 38.33M |
| September 30, 2024 | 39.62M |
| June 30, 2024 | 35.33M |
| March 31, 2024 | 36.43M |
| December 31, 2023 | 44.31M |
| September 30, 2023 | 44.14M |
| June 30, 2023 | 43.78M |
| March 31, 2023 | 43.80M |
| December 31, 2022 | 39.74M |
| September 30, 2022 | 42.82M |
| June 30, 2022 | 46.26M |
| March 31, 2022 | 47.98M |
| December 31, 2021 | 42.15M |
| Date | Value |
|---|---|
| September 30, 2021 | 37.46M |
| June 30, 2021 | 32.56M |
| March 31, 2021 | 27.04M |
| December 31, 2020 | 29.17M |
| September 30, 2020 | 34.24M |
| June 30, 2020 | 42.81M |
| March 31, 2020 | 48.54M |
| December 31, 2019 | 49.10M |
| September 30, 2019 | 47.41M |
| June 30, 2019 | 38.98M |
| March 31, 2019 | 31.11M |
| December 31, 2018 | 29.21M |
| September 30, 2018 | 26.36M |
| June 30, 2018 | 23.15M |
| March 31, 2018 | 20.60M |
| December 31, 2017 | 16.46M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (TTM) Benchmarks
| MediGene AG | -- |
| BioNTech SE | 2.414B |
| Immatics NV | 254.72M |
| Beam Therapeutics, Inc. | 408.66M |
| Kymera Therapeutics, Inc. | 367.34M |